Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 265 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Food Sensitivity Clear all
Completed Not applicable Interventional

CHARGE: Controlling Hunger and ReGulating Eating

NCT03678766
View directory record Official record
Conditions
Binge-Eating Disorder, Overweight, Obesity
Interventions
Regulation of Cues (ROC), Cognitive Behavior Therapy (CBT)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess Full-fat or Low-fat Dairy Foods on Insulin Sensitivity, RBC FA's and Other Markers of Metabolic Health

NCT04999462
View directory record Official record
Conditions
Overweight and Obesity, Elevated Triglycerides
Interventions
Full-fat fermented dairy, Low-fat fermented dairy, Non-dairy, non-fermented foods
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Miami Gardens, Florida • Chicago, Illinois • Gurnee, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

NCT07117669
View directory record Official record
Conditions
Peanut Allergy
Interventions
ENP-501, Placebo
Drug
Lead sponsor
N-Fold, LLC
Industry
Eligibility
14 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
3 Months to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Completed No phase listed Observational

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

NCT02953223
View directory record Official record
Conditions
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome, Multiple Food Allergies
Interventions
Free amino acid infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Day to 12 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 22, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

NCT04984876
View directory record Official record
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Early Phase 1 Interventional

Xolair Treatment for Milk Allergic Children

NCT00968110
View directory record Official record
Conditions
Milk Allergy
Interventions
omalizumab
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 22, 2026, 4:58 PM EDT
Not yet recruiting Phase 2 Interventional

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG

NCT07611435
View directory record Official record
Conditions
Alpha-Gal Syndrome, Allergy
Interventions
DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork
Diagnostic Test
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy, Omalizumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

NCT01675882
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects

NCT02590289
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
BBI-5000
Drug
Lead sponsor
Fresh Tracks Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Jul 22, 2026, 4:58 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

NCT07566325
View directory record Official record
Conditions
Overweight (BMI > 25), Obesity (BMI>30), Hs-CRP
Interventions
Avocado, Control
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
21 Years to 74 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Chicago, Illinois • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Food Allergen OIT for Shrimp and Cashew

NCT03504774
View directory record Official record
Conditions
Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
Interventions
Cashew or Shrimp Oral Immunotherapy
Drug
Lead sponsor
Sayantani B. Sindher
Other
Eligibility
7 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional

Omalizumab Weight-Based Dosing Efficacy Trial

NCT06943534
View directory record Official record
Conditions
Allergies, Food Allergy
Interventions
5mg/kg omalizumab injection, 15mg/kg omalizumab injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 4:58 PM EDT
Active, not recruiting Phase 4 Interventional

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

NCT06437171
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab
Biological
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 4:58 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy

NCT00602160
View directory record Official record
Conditions
Food Allergy
Interventions
FAHF-2 (TM)
Drug
Lead sponsor
Li, Xiu-Min, M.D.
Individual
Eligibility
12 Years to 45 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients

NCT03463135
View directory record Official record
Conditions
Food Allergy
Interventions
Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE), Placebo for GLA, Placebo for SLIT PE
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Little Rock, Arkansas • Mission Viejo, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 22, 2026, 4:58 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Skin Barrier Abnormalities and Oxidative Stress Response

NCT04606615
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
1 Year to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects.

NCT03332927
View directory record Official record
Conditions
PreDiabetes
Interventions
Egg based breakfast foods, Non-egg based breakfast foods
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

NCT01846208
View directory record Official record
Conditions
Food Allergy
Interventions
Egg Oral Immunotherapy, Baked Egg
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
3 Years to 16 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy

NCT00664768
View directory record Official record
Conditions
Cow Milk Allergy
Interventions
Neocate Infant, new Neocate
Dietary Supplement
Lead sponsor
Nutricia North America
Industry
Eligibility
1 Day to 8 Months
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Chandler, Arizona • Tucson, Arizona • Bentonville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Inhibition of Anaphylaxis by Ibrutinib

NCT03149315
View directory record Official record
Conditions
Food Allergy, Anaphylaxis Food
Interventions
Ibrutinib
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitive Periods in Early Flavor Learning

NCT00994747
View directory record Official record
Conditions
Healthy
Interventions
Nutramigen (Flavor and Type of Infant Formula), Enfamil, milk-based formula
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jul 22, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 22, 2026, 4:58 PM EDT